Analyst estimates based on growth trends
1. Humira
Annual Sales 14,021M Annual Growth 11.8%
Manufactured by: AbbVie Inc. (U.S.)
Rheumatoid Arthritis and other inflammatory conditions.
The composition patent of this product will expire in December 2016 in the U.S and October 2018 in the Europe.
2. Harvoni
Annual Sales 13,864 M Annual Growth 551.8%
Manufactured by: Gilead Science Inc. (U.S.)
Hepatitis C
The patent for the product will expire in 2030, making it an important candidate in Gileade’s pstent estates.
3. Enbrel
Annual Sales 90,27 M Annual Growth 1.2%
Manufactured by: Amgen Inc. (U.S.) , Takeda Pharmaceutical Company Limited (Japan)
Rheumatoid arthritis psoriasis and other inflammatory condition.
Patent of the product will expire in August 2019.
4. Remicade
Annual Sales 8,957 M Annual Growth -9.4%
Manufactured by: Johnson & Johnsons (U.S.) , Merck & Co. (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan)
Takeda Pharmaceutical Company Limited (Japan)
Anti-TNF alpha drug for inflammatory disorders.
Patent of the product will expire in September 2018.
5. Lantus
Annual Sales 7,209 M Annual Growth 0.7%
Manufactured by: jSanofi S.A. (France)
Diabetes
The U.S patent for the product expired in August 2014.
6. Avastin
Annual Sales 6,905 M Annual Growth 4.2%
Manufactured by: JF. Hoffmann-LA Roche AG (Switzerland)
Cancer
The U.S patent for the product will expire in 2019.
7. Herceptin
Annual Sales 6,754 M Annual Growth 4.2%
Manufactured by: JF. Hoffmann-LA Roche AG (Switzerland)
Anti HER2 for breast Cancer
The U.S patent for the product is set to expire in 2019.
8. Prevnar
Annual Sales 6,254 M Annual Growth 39.9%
Manufactured by: Pfizer Inc. (U.S.)
Pneumococcal Vaccine
The U.S patent for the product will expire in 2026.
9. MabThera/Rituxan
Annual Sales 5,827 M Annual Growth 0.7%
Manufactured by: JF. Hoffmann-LA Roche AG (Switzerland)
Cancer
Sales of the product are expected to decline after the expiry of its U.S patent in 2015.
10. Revlimid
Annual Sales 5,801 M Annual Growth 16.5%
Manufactured by: Celgene Corporation (U.S.) – Multiple
Myeloma
The U.S patent is expected to expire in 2027.
11. Crestor
Annual Sales 5,427 M Annual Growth -8.2%
Manufactured by: AstraZeneca plc (U.K.), Shionogi & Co. Ltd. (Japan)
Diabetes
The U.S patent for the product expired in January 2016.
12. Sovaldi
Annual Sales 5,276 M Annual Growth -48.7%
Manufactured by: Gilead Sciences, Inc. (U.S)
Hepatitis C
The U.S patent for the product will expire in January 2029.
13. Seretide / Advair
Annual Sales 5,228 M Annual Growth -13.0%
Manufactured by: GlaxoSmithKline plc (U.K.)
Asthma
The sales are expected to decline further after the U.S. patent expiry in 2016
14. Copaxone
Annual Sales 5,213 M Annual Growth -6.5%
Manufactured by: Teva Pharmaceutical Industries Ltd.
Multiple Sclerosis
However, the sales of the product declined since the expiry of U.S patent in May 2014.
15. Neulasta
Annual Sales 4,715 M Annual Growth 2.6%
Manufactured by: Amgen Inc. (U.S.)
Leukocyte Growth Factor
The U.S. patent for the product expired in June 2015.
16. Gleevec / Glivec
Annual Sales 4,658 M Annual Growth -1.9%
Manufactured by: Novartis AG (Switzerland)
Cancer
The U.S. patent for the product expired in July 2015.
17. Xarelto
Annual Sales 4,409 M Annual Growth 29.1%
Manufactured by: Bayer AG (Germany), Johnson & Johnson (U.S.)
Anticoagulant
The U.S. patent for the product will expire in 2020.
18. Januvia
Annual Sales 3,864 M Annual Growth -1.7%
Manufactured by: Merck & Co. (U.S.)
Diabetes
The U.S. patent for the product will expire in 2022.
19. Lyrica
Annual Sales 3,655 M Annual Growth 9.1%
Manufactured by: Pfizer Inc. (U.S.)
Ani-epileptic
The U.S. patent for the product will expire in 2018.
20. Lucentis
Annual Sales 3,630 M Annual Growth -13.5%
Manufactured by: Novartis AG (Switzerland), F. Hoffmann-LA Roche AG (Switzerland)
Macular Degeneration
21. Truvada
Annual Sales 3,459 M Annual Growth 3.6%
Manufactured by: Gilead Science Inc. (U.S.)
HIV
The U.S. patent for the product will expire in 2021.
22. Symbicort
Annual Sales 3,394 M Annual Growth -10.7%
Manufactured by: AstraZeneca plc (U.K.)
Asthma
23. Spiriva
Annual Sales 3,201 M Annual Growth -12.3%
Manufactured by: Boehringer Ingelheim GmbH (Germany)
Bronchospasm
24. Nexium
Annual Sales 3,196 M Annual Growth -25.5%
Manufactured by: AstraZeneca plc (U.K.), Daiichi Sankyo Company Ltd. (Japan)
Gastro esophageal Reflux Disease
25. Atripla
Annual Sales 3,134 M Annual Growth -9.7%
Manufactured by: Gilead Science Inc. (U.S.)
HIV
The U.S. patent for the product will expire in 2021.
Reference:
http://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf
https://www.imshealth.com/files/web/Corporate/News/Top-Line%20Market%20Data/Global%20Prescription%20Sales%20Information5%20World%20figures%20by%20Region%202015-2019.pdf
http://labiotech.eu/roches-patent-halts-an-amgen-biosimilar-debut/%20http:/www.drugdevelopment-technology.com/features/featureten-blockbuster-drugs-that-lost-patent-in-2014-4445799/
http://www.nature.com/nrd/journal/v11/n6/fig_tab/nrd3749_T1.html
http://www.fiercepharma.com/special-report/top-20-drugs-2020-worldwide-sales
IGAHUB
http://www.gabionline.net/Reports/Opportunities-in-the-COPD-market
http://qz.com/349929/best-selling-drugs-in-the-world/
http://www.uspto.gov/patent/laws-and-regulations/patent-term-extension/patent-terms-extended-under-35-usc-156
